AGEN
Agenus Inc
NASDAQ: AGEN · HEALTHCARE · BIOTECHNOLOGY
$6.94
+0.73% today
Updated 2026-09-11
Market cap
$310.19M
P/E ratio
2.30
P/S ratio
2.34x
EPS (TTM)
$3.00
Dividend yield
—
52W range
$3 – $9
Volume
5.1M
WallStSmart proprietary scores
58
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B5.0
Quality
C+7.5
Profitability
B+7.0
Valuation
B+5/9
Piotroski F-Score
Moderate
-13.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$19.50
+180.98%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 69.30% — above average
+ Revenue growth 34.40% QoQ
+ Debt/equity -0.20x — low leverage
Risks
- Altman Z -13.22 — distress zone
- Negative free cash flow $-31.20M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $98.02M | $156.31M | $103.46M | $114.20M | $132.69M |
| Net income | $-220.07M | $-245.76M | $-227.21M | $115000.00 | $-550000.00 |
| EPS | — | — | — | — | $3.00 |
| Free cash flow | $-228.44M | $-234.16M | $-158.89M | $-158.89M | $-31.20M |
| Profit margin | -224.51% | -157.22% | -219.61% | 0.10% | 69.30% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-10 | ARMEN, GARO H | Buy | 1,971,500 | — |
| 2026-08-05 | WRIGHT, TIMOTHY | Buy | 50,000 | — |
| 2026-08-05 | O'DAY, STEVEN J | Buy | 100,000 | — |
Peer comparison
Smart narrative
Agenus Inc trades at $6.94. representing a P/E of 2.30x trailing earnings. Our Smart Value Score of 58/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -13.22, it sits in the distress. TTM revenue stands at $132.69M. with profit margins at 69.30%.
Frequently asked questions
What is Agenus Inc's stock price?
Agenus Inc (AGEN) trades at $6.94, on a P/E of 2.3x and a P/S of 2.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Agenus Inc overvalued?
Agenus Inc carries a Smart Value Score of 58/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Agenus Inc (AGEN)?
The 12-month analyst consensus target is $19.50, about 181.0% above the current $6.94. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Agenus Inc's revenue?
Agenus Inc's trailing twelve-month revenue is $132.69M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Agenus Inc's Altman Z-Score is -13.22, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.34x
ROE-1,279.00%
Beta1.40
50D MA$6.44
200D MA$4.26
Shares out0.05B
Float0.04B
Short ratio—
Avg volume5.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—